GYNECOLOGIC CANCERS

The combination of durvalumab, chemotherapy, and bevacizumab, followed by maintenance with olaparib, durvalumab, and bevacizumab, improved progression-free survival in newly diagnosed advanced ovarian cancer.

NXP800 was granted orphan drug designation from the FDA in ARID1a-deficient ovarian, fallopian tube, and primary peritoneal cancers.

IMMN-001 significantly extended overall survival in patients with advanced ovarian cancer when combined with standard chemotherapy, according to phase 2 trial results.

Dostarlimab plus chemotherapy has been approved for the treatment of all forms of advanced endometrial cancer, including mismatch repair-deficient and microsatellite stable tumors.

Findings from the phase 2 NeoPembrOV study supported the addition of pembrolizumab to neoadjuvant chemotherapy before surgery in high-grade serous ovarian cancer.

Bhavana Pothuri, MD, discussed the importance of testing and accessing treatment for patients with endometrial cancer.

The FDA has approved an individual patient investigational new drug application, allowing for a second dose of a novel CAR T-cell therapy for a patient with recurrent ovarian cancer.

An analysis from the innovaTV 301 showed that tisotumab vedotin in the second- and third-line bettered overall survival vs investigator’s choice of chemotherapy in patients with cervical cancer.

A phase 2 trial demonstrated that nivolumab is effective and has a manageable safety profile in patients with mismatch repair deficiency uterine or ovarian cancers.

Premal Thaker, MD, discussed the ACCC Ovarian Quality of Care Project aiming to bridge the gap to improve ovarian cancer care for patients in the US.

Nivolumab plus ipilimumab demonstrates increased survival and response in patients with ovarian or gynecologic clear cell carcinoma.

CEE therapy alone in postmenopausal women after hysterectomy was linked to a substantial increase in ovarian cancer incidence and mortality.

Targeted therapies and immunotherapies across the ovarian, endometrial, and cervical cancers landscape play expanded roles, according to Ritu Salani, MD, MBA.

Sarah Lee, MD, MBA, discussed a study to better disaggregate the subgroup of Asian American patients with ovarian cancer.

The latest developments across the field of gynecologic oncology were presented at the 2024 Society for Gynecologic Oncology Annual Meeting on Women’s Cancer in San Diego, California, from March 16-18, 2024.

The use of ChatGPT may help to improve genetic counseling for patients with gynecologic cancer.

Treatment with nab-Sirolimus demonstrated promising response rates in patients with gynecologic PEComa, according to a subgroup analysis of the phase 2 AMPECT study.

Patient reported health-related quality of life outcomes from the phase 3 MIRASOL trial strengthen the case for mirvetuximab soravtansine as a new standard of care for patients with folate receptor-alpha positive ovarian cancer resistant to platinum chemotherapy.

The FDA orphan drug designation qualifies the sponsor of avutometinib for tax credits for clinical trials, exemption from user fees, and potential market exclusivity.

Findings from the phase 3b OReO study showed that patients with ovarian cancer who previously received a PARP inhibitor benefitted from a rechallenge with olaparib.

In an interview with Targeted Oncology, Eric Schroeder, MD, discussed the transformative shift that the landscape of ovarian cancer treatment has undergone in recent years.

Rates of enrollment in clinical trials were notably lower among Asian, Black, and Hispanic patients with gynecologic cancers compared with White women.

The combination of pembrolizumab and lenvatinib appears to be effective in for the treatment of patients with endometrial cancer, regardless of biomarker status.

Positive findings from the KEYNOTE-A18 trial support the approval of pembrolizumab, radiotherapy, and concurrent chemotherapy in patients with high-risk locally advanced cervical cancer.

RC88 is a mesothelin-targeting antibody-drug conjugate that offers a novel approach to treating platinum-resistant ovarian, fallopian tube, and peritoneal cancers.

The FDA has approved the new drug application of a ready-to-dilute formulation of a treatment for breast and ovary adenocarcinoma.

The supplemental biologics license application approval is based on findings from the phase 3 innovaTV 301 trial investigating tisotumab vedotin vs investigator’s choice of chemotherapy in cervical cancer.

Rinatabart sesutecan is an antibody drug conjugate that has now received a fast track designation from the FDA for the treatment of FRα-expressing ovarian cancer.

In an interview with Targeted Oncology, Eirwen M. Miller, MD, discussed the dynamic landscape of ovarian cancer treatment.

The phase 3 LEAP-001 trial did not meet its primary end points of overall survival and progression-free survival.